BACKGROUND: @entity1205 in combination with @entity900 or @entity136 are active chemotherapy reigimes against @entity1149 . We compared the efficacy and safety of a combination of @entity900 and @entity1205 (group 1) with that of @entity136 and @entity1205 (group 2) in the treatment of advanced @entity1149 in a prospective, randomised, multicentre trial. METHODS: @entity1 with stage IIIB or @entity2 who had not had prior chemotherapy were allocated either to group 1 and treated with @entity1205 (100 mg/m(2), day 1) and @entity900 (80 mg/m(2), day 2) or to group 2 and treated with @entity136 (1100 mg/m(2), days 1 and 8) and @entity1205 (100 mg/m(2), day 8). All @entity1 received recombinant @entity1 @entity1261 (150 mg/m(2)). All @entity1 received recombinant @entity1 @entity1261 (150 mg/m(2)) had appropriate standard premedication. Response and @entity137 were assessed using WHO criteria. Analysis was by intention to treat. FINDINGS: 441 @entity1 were randomly assigned to receive @entity1205 / @entity900 (group 1, n=219) or @entity136 / @entity1205 (group 2, n=222). 14 @entity1 in group 1 and 21 @entity1 in group 2 were not evaluable. Objective response rates were similar in the two groups: group 1, 32.4% (95% CI 26.2-38.6%; 1.4% complete response and 31% partial response); group 2, 30.2% (24.5-36.2%; 0.9% complete response and 29.3% partial response). The two groups did not differ in median duration of response, time to @entity5 progression, overall survival, or 1 year or 2 year survival rates. INTERPRETATION: Both drug combinations had comparable activity in @entity1 with advanced @entity5 who had not previously had chemotherapy; however, @entity136 and @entity1205 had the most favourable @entity137 profile.

Platinum-based and non-platinum-based chemotherapy in advanced XXXX : a randomised multicentre trial.

@entity1 :: ('9606', 'Species') :: ['Patients', 'human', 'patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity1261 :: ('1440', 'Gene') :: ['granulocyte colony-stimulating factor'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'tumour'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['non-small-cell lung cancer'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['Docetaxel', 'docetaxel'] @entity2 :: ('MESH:D008175', 'Disease') :: ['IV lung cancer'] @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine']
@entity1149 :: (MESH:D002289,Disease) :: ['non-small-cell lung cancer']
